The new deal builds on existing collaborations between the two companies, which struck a software licensing agreement in 2023, according to Insilico. The pair will use Insilico's "AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas", said the filing, made by Insilico's parent company on Sunday.